DR. EVAN M BECKMAN
Osteopathic Medicine at Moffat Rd, Newton, MA
License number
Massachusetts 73977
Category
Osteopathic Medicine
Type
Rheumatology
Address
Address
125 Moffat Rd, Newton, MA 02468
Phone
(617) 916-1685
Personal information
See more information about EVAN M BECKMAN at radaris.comName
Address
Phone
128 Fuller St, West Newton, MA 02465
81 Newbridge Rd, Sudbury, MA 01776
Newton, MA
125 Moffat Rd, Waban, MA 02468
128 Fuller St, West Newton, MA 02465
Professional information
See more information about EVAN M BECKMAN at trustoria.com
Dr. Evan M Beckman, Waban MA - MD (Doctor of Medicine)
Dr. Evan M Beckman, Waban MA - MD (Doctor of Medicine)
Specialties:
Rheumatology
Address:
125 Moffat Rd, Waban 02468
(617) 916-1685 (Phone)
(617) 916-1685 (Phone)
Certifications:
Internal Medicine, 1991, Rheumatology, 1994
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Perelman School of Medicine University of Pennsylvania
Graduated: 1988
Hospital Of The University Of Pennsylvania
Brigham and Womens Hospital
Perelman School of Medicine University of Pennsylvania
Graduated: 1988
Hospital Of The University Of Pennsylvania
Brigham and Womens Hospital
Compositions Comprising Variant Lt-B-R-Ig Fusion Proteins
Compositions Comprising Variant Lt-B-R-Ig Fusion Proteins
US Patent:
8338376, Dec 25, 2012
Filed:
Sep 15, 2009
Appl. No.:
12/560257
Inventors:
Evan Beckman - Newton MA, US
Graham K. Farrington - Acton MA, US
Werner Meier - Burlington MA, US
Jeffrey L. Browning - Brookline MA, US
Graham K. Farrington - Acton MA, US
Werner Meier - Burlington MA, US
Jeffrey L. Browning - Brookline MA, US
Assignee:
Biogen Idec MA Inc. - Cambridge MA
International Classification:
A61K 38/00, A61K 38/16, A61K 45/00, C12P 21/06, C12P 21/04, C12N 15/00, C12N 5/00, C07H 21/04, C07K 1/00, C07K 14/00
US Classification:
514 166, 514 212, 4242781, 435 691, 435 697, 435 703, 4353201, 435325, 536 234, 536 235, 530350, 530402
Abstract:
This invention relates to methods of treating disease with soluble inhibitors of the lymphotoxin pathway having improved properties. This invention also relates to improved LTBR-Ig fusion proteins, and pharmaceutical compositions thereof.